Side by side

David Evendon-Challis and Dr John Creek on why collaboration will be key in developing credible microbiome solutions
Transforming the landscape

How big tech and big pharma partnerships are providing deeper insights and improving patient outcomes
In the shadows

The pharma industry may just have more unsung heroes than any other.

News

View all

Astellas, Audentes pen $3bn gene therapy deal

Genetic regulation is set to become a fifth primary focus for the Japanese drugmaker, on top of its already existing business lines.

6th December 2019

Novartis, Amazon ink deal for ‘smart’ manufacturing

The online retail giant's honed data abilities will help Novartis produce more personalised therapies.

6th December 2019

ViiV Healthcare submits HIV drug fostemsavir in the US

The treatment could offer a new option for patients unable to reach viral supression

6th December 2019

PharmaTimes unveils winners of MSEA 2019

This year's competition welcomed a fantastic spread of companies as well as a higher number of entrants

6th December 2019

INTCR 2020 Executive Steering Group Chair shares insight into this ever-growing competition

Flying the flag for clinical research for over 20 years, this competition continues to grow and develop year after year.

5th December 2019

Web Exclusives

View all

SmartPeople: David Logue

PharmaTimes talks to David Logue, senior vice president of commercial strategy at Veeva

Can private GP services benefit patients who can’t afford them?

Jessica Foreman looks at arguments for and against private GP services

Prepare to engage

After the election, Brexit will finally become real. Pharma must be ready to engage or risks being left behind.

Thumbnail image for Removing the barriers

Merck's Maria Rivas discusses findings from the Supporting Women With Cancer report, which reveals some of the challenges associated with screening for cancer in women, and what more could be done to support the earlier detection of cancer and improve chances of survival.

Magazine

View more from the latest edition

Smart People: Hilary Hutton-Squire

PharmaTimes talks to Hilary Hutton-Squire, vice president and general manager of Gilead Sciences in the UK and Ireland, about the importance of valuing medicines in the right way

A clearer picture

Marni Hall and Nicola Stanislaus look at the growing role of real-word evidence

Raising the bar

A 2019 review has shown that the current system for detecting cancer is failing to reach its potential. Fujifilm’s Adrian Waller says we need a more tech-enabled and patient-centred approach

The year of no Brexit (again)

Political uncertainty became endemic during 2019, despite a lot of government planning

2019 – the return of the mega deal?

Globally mega deals continue to abound, domestically the mid-market and PE have been the core drivers of activity

Unlocking value

How can 2020 be the year that R&D really delivers value, people get real about data, and pharma starts to develop even better medicines?

Bag to the future

For decades intrepid pharma sales forces navigated the road network of Great Britain with little more than paper, pen and personality – hoping that one day the tools of their trade would mirror the cutting-edge science of the products they showcased. In recent years, the digital era has truly arrived, but as 2020 looms, big challenges still remain